IDYA vs IONS: fair value comparison
IDEAYA Biosciences, Inc. and Ionis Pharmaceuticals, Inc. · Updated 2026-10-19
IDYA has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. IONS has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, IDYA currently ranks higher by quality score.
| IDYA | IONS | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $32.85 | $42.94 |
| 12-month range | $27.60–$42.48 | $42.38–$86.50 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #143 of 301 Healthcare | #144 of 301 Healthcare |
| Quality grade | D | D |
| Leverage | Low | High |
| Margin trend | Contracting | Stable |
| Revenue growth | Modest | High |
| RSI zone | Oversold | Neutral |
| 50/200-day trend | Mixed | Downtrend |
| 52-week position | The lower-middle quarter | The bottom quarter |
Full single-stock breakdowns: IDYA fair value analysis · IONS fair value analysis